315 related articles for article (PubMed ID: 35343213)
1. Therapeutic drug monitoring for biological medications in inflammatory bowel disease.
Cogan RC; El-Matary BW; El-Matary WM
Saudi J Gastroenterol; 2022; 28(5):322-331. PubMed ID: 35343213
[TBL] [Abstract][Full Text] [Related]
2. Challenges in Therapeutic Drug Monitoring: Optimizing Biological Treatments in Patients With Inflammatory Bowel Disease and Other Immune-Mediated Inflammatory Diseases.
Papamichael K; Stocco G; Ruiz Del Agua A
Ther Drug Monit; 2023 Oct; 45(5):579-590. PubMed ID: 37012629
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic drug monitoring in inflammatory bowel disease: for every patient and every drug?
Papamichael K; Cheifetz AS
Curr Opin Gastroenterol; 2019 Jul; 35(4):302-310. PubMed ID: 30973355
[TBL] [Abstract][Full Text] [Related]
4. Proactive Therapeutic Drug Monitoring of Adalimumab Is Associated With Better Long-term Outcomes Compared With Standard of Care in Patients With Inflammatory Bowel Disease.
Papamichael K; Juncadella A; Wong D; Rakowsky S; Sattler LA; Campbell JP; Vaughn BP; Cheifetz AS
J Crohns Colitis; 2019 Aug; 13(8):976-981. PubMed ID: 30689771
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic drug monitoring in patients on biologics: lessons from gastroenterology.
Papamichael K; Cheifetz AS
Curr Opin Rheumatol; 2020 Jul; 32(4):371-379. PubMed ID: 32412995
[TBL] [Abstract][Full Text] [Related]
6. Proactive Therapeutic Drug Monitoring of TNF Antagonists in Inflammatory Bowel Disease.
Roblin X; Riviere P; Flamant M; Veyrard P; Poullenot F; Paul S; Laharie D
Inflamm Bowel Dis; 2018 Aug; 24(9):1904-1909. PubMed ID: 29726958
[TBL] [Abstract][Full Text] [Related]
7. Appropriate Therapeutic Drug Monitoring of Biologic Agents for Patients With Inflammatory Bowel Diseases.
Papamichael K; Cheifetz AS; Melmed GY; Irving PM; Vande Casteele N; Kozuch PL; Raffals LE; Baidoo L; Bressler B; Devlin SM; Jones J; Kaplan GG; Sparrow MP; Velayos FS; Ullman T; Siegel CA
Clin Gastroenterol Hepatol; 2019 Aug; 17(9):1655-1668.e3. PubMed ID: 30928454
[TBL] [Abstract][Full Text] [Related]
8. Improved Long-term Outcomes of Patients With Inflammatory Bowel Disease Receiving Proactive Compared With Reactive Monitoring of Serum Concentrations of Infliximab.
Papamichael K; Chachu KA; Vajravelu RK; Vaughn BP; Ni J; Osterman MT; Cheifetz AS
Clin Gastroenterol Hepatol; 2017 Oct; 15(10):1580-1588.e3. PubMed ID: 28365486
[TBL] [Abstract][Full Text] [Related]
9. Personalized Dosing of Infliximab in Patients With Inflammatory Bowel Disease Using a Bayesian Approach: A Next Step in Therapeutic Drug Monitoring.
Desai DC; Dherai AJ; Strik A; Mould DR
J Clin Pharmacol; 2023 Apr; 63(4):480-489. PubMed ID: 36458468
[TBL] [Abstract][Full Text] [Related]
10. Review article: consensus statements on therapeutic drug monitoring of anti-tumour necrosis factor therapy in inflammatory bowel diseases.
Mitrev N; Vande Casteele N; Seow CH; Andrews JM; Connor SJ; Moore GT; Barclay M; Begun J; Bryant R; Chan W; Corte C; Ghaly S; Lemberg DA; Kariyawasam V; Lewindon P; Martin J; Mountifield R; Radford-Smith G; Slobodian P; Sparrow M; Toong C; van Langenberg D; Ward MG; Leong RW;
Aliment Pharmacol Ther; 2017 Dec; 46(11-12):1037-1053. PubMed ID: 29027257
[TBL] [Abstract][Full Text] [Related]
11. Proactive Infliximab Drug Monitoring Is Superior to Conventional Management in Inflammatory Bowel Disease.
Fernandes SR; Bernardo S; Simões C; Gonçalves AR; Valente A; Baldaia C; Moura Santos P; Correia LA; Tato Marinho R
Inflamm Bowel Dis; 2020 Jan; 26(2):263-270. PubMed ID: 31247074
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic drug monitoring with biologic agents in immune mediated inflammatory diseases.
Papamichael K; Vogelzang EH; Lambert J; Wolbink G; Cheifetz AS
Expert Rev Clin Immunol; 2019 Aug; 15(8):837-848. PubMed ID: 31180729
[No Abstract] [Full Text] [Related]
13. Clinical Outcomes With Therapeutic Drug Monitoring in Inflammatory Bowel Disease: A Systematic Review With Meta-Analysis.
Ricciuto A; Dhaliwal J; Walters TD; Griffiths AM; Church PC
J Crohns Colitis; 2018 Nov; 12(11):1302-1315. PubMed ID: 30107416
[TBL] [Abstract][Full Text] [Related]
14. Ultra-proactive Therapeutic Drug Monitoring of Infliximab Based on Point of Care Testing in Inflammatory Bowel Disease: Results of a Pragmatic Trial.
Bossuyt P; Pouillon L; Claeys S; D'Haens S; Hoefkens E; Strubbe B; Marichal D; Peeters H
J Crohns Colitis; 2022 Feb; 16(2):199-206. PubMed ID: 34297099
[TBL] [Abstract][Full Text] [Related]
15. A 3-year prospective study of a multidisciplinary early proactive therapeutic drug monitoring programme of infliximab treatments in inflammatory bowel disease.
Sánchez-Hernández JG; Rebollo N; Martin-Suarez A; Calvo MV; Muñoz F
Br J Clin Pharmacol; 2020 Jun; 86(6):1165-1175. PubMed ID: 32022291
[TBL] [Abstract][Full Text] [Related]
16. Advantages of Proactive Therapeutic Drug Monitoring in a Prospective Cohort of Children With Inflammatory Bowel Disease Treated With Anti-Tumour Necrosis Factor.
Gasparetto M; Burgess N; Naik S; Studart D; Kadir A; Croft N; Sanderson I; Deb P
J Pediatr Gastroenterol Nutr; 2022 Apr; 74(4):484-489. PubMed ID: 35129158
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic Drug Monitoring in Pediatric Inflammatory Bowel Disease.
Carman N; Mack DR; Benchimol EI
Curr Gastroenterol Rep; 2018 Apr; 20(5):18. PubMed ID: 29623442
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic drug monitoring in inflammatory bowel disease: The dawn of reactive monitoring.
Albader F; Golovics PA; Gonczi L; Bessissow T; Afif W; Lakatos PL
World J Gastroenterol; 2021 Oct; 27(37):6231-6247. PubMed ID: 34712029
[TBL] [Abstract][Full Text] [Related]
19. Review article: determination of the therapeutic range for therapeutic drug monitoring of adalimumab and infliximab in patients with inflammatory bowel disease.
Gibson DJ; Ward MG; Rentsch C; Friedman AB; Taylor KM; Sparrow MP; Gibson PR
Aliment Pharmacol Ther; 2020 Mar; 51(6):612-628. PubMed ID: 31961001
[TBL] [Abstract][Full Text] [Related]
20. Predictors of Infliximab Trough Concentrations in Inflammatory Bowel Disease Patients Using a Repeated-Measures Design.
Santacana E; Rodríguez-Alonso L; Padullés A; Guardiola J; Bas J; Rodríguez-Moranta F; Serra K; Morandeira F; Colom H; Padullés N
Ther Drug Monit; 2020 Feb; 42(1):102-110. PubMed ID: 31283556
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
